Endometrial Cancer Trial, Recruiting NCT04723095 Sponsor: M.D. Anderson Cancer Center Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04723095
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a personal history of cervical cancer that includes a neuroendocrine component, including mixed tumours, specifically of the small cell, large cell, or undifferentiated high-grade type.
  • People at any stage — whether currently in treatment, being monitored after treatment, or experiencing a return of cancer — may be considered.
  • People with any stage of disease may be considered.
  • People who do not speak English may be considered if an interpreter provided by the institution is present during participation.
  • People who have received or are currently receiving treatment at any hospital or cancer centre, not just MD Anderson Cancer Center, may be considered.
  • People living in any country and of any ethnic background may be considered.
  • People who wish to take part, including those who find out about the trial through the trial website, may be considered.
  • Family members or legal representatives of a person who has passed away but had a history of neuroendocrine carcinoma of the cervix may also be considered for participation.
  • Family members or legal representatives participating on behalf of a deceased patient must be able to read and speak English.

Who may not be able to join:

  • People whose cervical cancer is of a neuroendocrine type known as a carcinoid tumour — either typical or atypical — may not be eligible for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Larissa A. Meyer, M.D. Anderson Cancer Center

Phone: 713-745-0973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 May 2013
Est. completion
1 January 2044

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Disease characterization data; Patient treatment data; Patient outcome data

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov